180 Life Sciences Corp. to Ring Nasdaq Opening Bell on November 27, 2020
November 24 2020 - 10:00AM
180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences
or the "Company"), a clinical-stage biotechnology company with its
lead indication in Phase 2b/3, focused on the development of novel
drugs that fulfill unmet needs in inflammatory diseases, fibrosis
and pain, today announced that it will ring the Nasdaq Stock
Exchange opening bell on November 27, 2020, in celebration of its
recently completed initial public offering.
Dr. James Woody, CEO of 180 Life Sciences, will be joined by
members of the 180 Life Sciences team for the virtual ceremony,
which will begin at approximately 9:20 am Eastern Time, and can be
viewed live at
https://livestream.com/nasdaq/live and on the
Nasdaq MarketSite Tower in Times Square, at 43rd Street and
Broadway, New York, NY. The bell ringing will take place at 9:30am
Eastern Time, signifying the start of the day’s trading
session. Dr. James Woody commented, “I am honored to be
ringing the Nasdaq opening bell on behalf of everyone at 180 Life
Sciences. We are on a mission to develop novel drugs that fulfill
unmet needs in inflammatory diseases, fibrosis and pain by
leveraging the combined expertise of luminaries in therapeutics
from Oxford University, the Hebrew University and Stanford
University. We are thrilled to mark the significant milestone of
becoming a public company with a bell ringing ceremony and look
forward to celebrating future milestones with our public
shareholders.”
180 Life Sciences is leading the research into solving one of
the world’s biggest drivers of disease – inflammation. The company
is driving groundbreaking studies into clinical programs, which are
seeking to develop novel drugs addressing separate areas of
inflammation for which there are no effective therapies. The
company’s primary platform is a novel program to treat fibrosis and
inflammation using anti-TNF, with its lead program in phase 2b/3
clinical trial.
About 180 Life Sciences Corp.
180 Life Sciences Corp. is a clinical-stage biotechnology
company focused on the development of novel drugs that fulfill
unmet needs in inflammatory diseases, fibrosis and pain by
leveraging the combined expertise of luminaries in therapeutics
from Oxford University, the Hebrew University and Stanford
University. 180 Life Sciences is leading the research into solving
one of the world’s biggest drivers of disease – inflammation. The
Company is driving groundbreaking studies into clinical programs,
which are seeking to develop novel drugs addressing separate areas
of inflammation for which there are no effective therapies. The
Company’s primary platform is a novel program to treat fibrosis
using anti-TNF (tumor necrosis factor), with its lead program in
phase 2b/3 clinical trials.
Forward-Looking StatementsThis press release
includes "forward-looking statements", including information about
management’s view of the Company’s future expectations, plans and
prospects, within the safe harbor provisions under The Private
Securities Litigation Reform Act of 1995 (the “Act”). Words such as
“expect,” “estimate,” “project,” “budget,” “forecast,”
“anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,”
“believes,” “predicts,” “potential,” “continue” and similar
expressions are intended to identify such forward-looking
statements. These forward-looking statements involve significant
risks and uncertainties that could cause the actual results to
differ materially from the expected results and, consequently, you
should not rely on these forward-looking statements as predictions
of future events. These forward-looking statements and factors that
may cause such differences include, without limitation, statements
relating to the continued listing of the Company on The NASDAQ
Stock Market; expectations regarding the capitalization, resources
and ownership structure of the Company; expectations with respect
to future performance, growth and anticipated acquisitions; the
ability of the Company to execute its plans to develop and market
new drug products and the timing and costs of these development
programs; estimates of the size of the markets for its potential
drug products; potential litigation involving the Company or the
validity or enforceability of the intellectual property of the
Company; global economic conditions; geopolitical events and
regulatory changes; access to additional financing, and the
potential lack of such financing; and the Company’s ability to
raise funding in the future and the terms of such funding. These
risk factors and others are included from time to time in documents
the Company files with the Securities and Exchange Commission,
including, but not limited to, its Form 10-Ks, Form 10-Qs and Form
8-Ks, as well as in the definitive proxy statement/prospectus that
the Company filed in connection with the recent merger. These
reports and filings are available at www.sec.gov. All subsequent
written and oral forward-looking statements concerning the Company,
the transactions described herein or other matters and attributable
to the Company or any person acting on its behalf are expressly
qualified in their entirety by the cautionary statements above.
Readers are cautioned not to place undue reliance upon any
forward-looking statements, which speak only as of the date made.
The forward-looking statements included in this press release are
made only as of the date hereof. The Company cannot guarantee
future results, levels of activity, performance or achievements.
Accordingly, you should not place undue reliance on these
forward-looking statements. The Company does not undertake or
accept any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statement to reflect
any change in its expectations or any change in events, conditions
or circumstances on which any such statement is based, except as
otherwise provided by law.
Investors:
Jason AssadDirector of IR180 Life Sciences
Corp678-570-6791Jason@180lifesciences.com
Media Relations:
David SchullDavid.Schull@russopartnersllc.com (212) 845-4271
Eric AndoEric.Ando@russopartnersllc.com (646) 218-4604
180 Life Sciences (NASDAQ:ATNF)
Historical Stock Chart
From Mar 2024 to Apr 2024
180 Life Sciences (NASDAQ:ATNF)
Historical Stock Chart
From Apr 2023 to Apr 2024